AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)
March 10 2021 - 7:00AM
AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ:
AZRX), a company specializing in the development of targeted
non-systemic, recombinant therapies for gastrointestinal
(GI) diseases, announced today that James Sapirstein, Chairman
and Chief Executive Officer, will present during the Maxim Group
Emerging Growth Virtual Conference taking place Wednesday, March 17
to Thursday, March 18, 2021. All registered conference attendees
will be able to view the prerecorded virtual presentation.
During the presentation, Mr. Sapirstein will
provide an overview of AzurRx’s business and clinical development
programs and discuss anticipated 2021 milestones. Additionally,
during the conference, Mr. Sapirstein and members of the AzurRx
management team will be participating in virtual one-on-one
meetings with registered investors and pharmaceutical
companies.
Details of AzurRx’s presentation are as
follows:
Event: |
|
2021 Emerging Growth Virtual Conference |
|
Date: |
|
Wednesday, March 17 to
Thursday, March 18, 2021 |
|
Time:Registration: |
|
9:00 a.m. ET to 5:00 p.m.
EThttps://www.m-vest.com/events/2021-emerging-growth-virtual-conference |
|
About AzurRx BioPharma,
Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a
clinical stage biopharmaceutical company specializing in the
development of targeted, non-systemic therapies for
gastrointestinal (GI) diseases. The Company has a pipeline of three
gut-restricted GI clinical programs. The lead therapeutic candidate
is MS1819, a recombinant lipase for the treatment of exocrine
pancreatic insufficiency (EPI) in patients with cystic fibrosis and
chronic pancreatitis, currently in two Phase 2 clinical trials.
AzurRx is launching two clinical programs using proprietary
formulations of niclosamide, a pro-inflammatory pathway inhibitor;
FW-420, for grade 1 Immune Checkpoint Inhibitor-Associated Colitis
and diarrhea in oncology patients and FW-1022, for COVID-19
gastrointestinal infections. The Company is headquartered in Delray
Beach, Florida with clinical operations in Hayward, California. For
more information visit www.azurrx.com.
Forward-Looking Statements
This press release may contain certain
statements relating to future results which are forward-looking
statements. These statements are not historical facts, but instead,
represent only the Company’s belief regarding future events, many
of which, by their nature, are inherently uncertain and outside of
the Company’s control. It is possible that the Company’s actual
results and financial condition may differ, possibly materially,
from the anticipated results and financial condition indicated in
these forward-looking statements, depending on factors including
whether results obtained in preclinical and nonclinical studies and
clinical trials will be indicative of results obtained in future
clinical trials; whether preliminary or interim results from a
clinical trial such as the interim results presented will be
indicative of the final results of the trial; and the Company’s
success in raising additional financing to support its operations.
Additional information concerning the Company and its business,
including a discussion of factors that could materially affect the
Company’s financial results, including those related to the
clinical development of MS1819, the results of its clinical trials,
and the impact of the coronavirus (COVID-19) pandemic on the
Company’s operations and current and planned clinical trials,
including, but not limited to delays in clinical trial recruitment
and participation are contained in the Company’s Annual Report on
Form 10-K for the year ended December 31, 2019 under the heading
“Risk Factors,” as well as the Company’s subsequent filings with
the Securities and Exchange Commission. All forward-looking
statements included in this press release are made only as of the
date of this press release, and we do not undertake any obligation
to publicly update or correct any forward-looking statements to
reflect events or circumstances that subsequently occur or of which
we hereafter become aware.
For more information:
AzurRx BioPharma, Inc.1615 South Congress
AvenueSuite 103Delray Beach, Florida 33445Phone: (646)
699-7855mailto:info@azurrx.com
Media contact:
Tiberend Strategic Advisors, Inc.Johanna
Bennett/Ingrid Mezo(212) 375-2665/(646)
604-5150jbennett@tiberend.com/imezo@tiberend.com
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Apr 2023 to Apr 2024